In this interview from the ASRS 2014 Annual Meeting, Dr. Jack Wells shares the 5-year outcomes for patients treated with ranibizumab (Lucentis) and a combination of prompt or deferred laser for the management of diabetic macular edema (DME). An arm of Protocol I of the DRCR.net, the study confirmed that eyes treated with ranibizumab and either prompt or deferred laser can maintain vision gains obtained in the first year through 5 years with minimal treatment after 3 years. Dr. Wells notes that deferring laser may be associated with better visual acuity (VA) through 5 years, especially in eyes with worse VA at baseline. He suspects this difference may be attributed to the greater number of ranibizumab injections performed during follow-up in the deferred group.